Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsOn July 15, 2022, the Company completed a public offering of 12,432,432 shares of common stock, including the exercise in full of the underwriters' option to purchase 1,621,621 additional shares of common stock. The shares were offered at a price to the public of $18.50 per share, resulting in aggregate proceeds of approximately $215.7 million, net of underwriting discounts, commissions and offering expenses. Subsequent to June 30, 2022, the Company initiated a retention award to employees consisting of 525,825 Restricted Stock Units (RSUs) with a 2 year vesting term. Additionally, senior management received a Performance RSU (PRSU) grant whereby the number of shares to vest is based on a target of 709,064 and will be increased or decreased based upon the Company's total shareholder return as measured against a relevant market index and according to the achievement of multiple clinical development milestones over the term of the award concluding in the second quarter of 2024. The minimum and maximum number of PRSUs to vest is 0% and 200% of target, respectively.